profit from every $100 of sales.
$0$100
Protalix BioTherapeutics
$3.05+3.04% today
+58.0% in 1 year
1-year low $1.671-year high $3.15
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Protalix BioTherapeutics sold, what it kept, and what it did with the cash.
Sales went from $47.6 million in 2022 to $52.7 million in 2025, with -$6.60 million of profit last year.
SalesProfit
Protalix BioTherapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Protalix BioTherapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Protalix BioTherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 48 | 65 | 53 | 53 | |
| 28 | 43 | 29 | 26 | |
| -13 | 10 | 4 | -6 | |
| -11 | 13 | 7 | -3 | |
| -15 | 8 | 3 | -7 | |
| -0.31 | 0.09 | 0.04 | -0.08 | |
| 58.9% | 64.9% | 54.5% | 48.8% | |
| -27.3% | 16.0% | 7.3% | -10.4% | |
| -31.3% | 12.7% | 5.5% | -12.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 56 | 84 | 73 | 82 |
| Cash | 17 | 24 | 20 | 15 |
| Total debt | 33 | 26 | 6 | 8 |
| Total liabilities | 66 | 51 | 30 | 34 |
| -11 | 34 | 43 | 48 | |
| 48 | 82 | 81 | 79 | |
| -41.1% | 15.5% | 8.5% | -6.2% | |
| 140.3% | 24.8% | 6.8% | -13.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -25 | -1 | 9 | -12 | |
| 1 | 1 | 1 | 2 | |
| -26 | -2 | 7 | -14 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 3 | 3 | 2 |
Valuation
- –
- 14.2×
- –
- 2.5×
- 4.9×
- –
- –
- -5.3%
- -2.6%
- 0.0%
Profitability
- 48.8%
- -10.4%
- -12.5%
- 27.9%
- 20.6%
- -31.6%
- 28.1%
- 15.0%
- 26.4%
- 28.2%
Growth
- +3.5%
- –
- −284.4%
- –
- +15.5%
Financial health
- -2.2×
- 0.13
- 8.3%
- 12.9×
- 3.15
- 2.04
- 0.75
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 6%of 952
Bottom 15%of 884
Bottom 25%of 886
Bottom 17%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | 0.22 | -0.01 | +2,300.0% |
| Mar 18, 2026 | -0.07 | 0.01 | −800.0% |
| Nov 13, 2025 | 0.03 | 0.06 | −50.0% |
| Aug 14, 2025 | 0.00 | 0.03 | −93.3% |
| May 9, 2025 | -0.05 | 0.08 | −162.5% |
| Mar 17, 2025 | 0.09 | 0.07 | +28.6% |
| Nov 14, 2024 | 0.03 | 0.06 | −50.0% |
| Aug 14, 2024 | -0.03 | -0.01 | −250.1% |
News
Protalix BioTherapeutics beats top-line and bottom-line estimates; reaffirms FY26 outlookSeeking Alpha · Nov 10, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
48No pass
Philip Fisher
34No pass
Peter Lynch
35No pass
Joel Greenblatt
25No pass
Charlie Munger
52No pass
Terry Smith
55No pass
Questions about Protalix BioTherapeutics
Is Protalix BioTherapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Protalix BioTherapeutics AI analysis
What does Protalix BioTherapeutics do?
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. It is in Biotechnology.
Does Protalix BioTherapeutics pay a dividend?
No. Protalix BioTherapeutics does not pay a dividend at the moment.
Is Protalix BioTherapeutics stock halal?
Yes. Protalix BioTherapeutics passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Protalix BioTherapeutics stock done over the past year?
Up 58.0% over the past twelve months, to $3.05. It traded between $1.67 and $3.15 and is 3.2% below its high.
Who are Protalix BioTherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Protalix BioTherapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.